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ABSTRACT 
Context  The medial frontal cortex (MFC), including the dorsal anterior cingulate and the 
supplementary motor area, is critical for adaptive and inhibitory control of behavior. Abnormally 
high MFC activity has been a consistent finding in functional neuroimaging studies of obsessive-
compulsive disorder (OCD). However, the precise regions and the neural alterations associated with 
this abnormality remain unclear. 
Objective  To examine the functional and biochemical properties of the MFC in patients with OCD. 
Design  Cross-sectional study combining volume-localized proton magnetic resonance spectroscopy 
and functional magnetic resonance imaging with a task encompassing inhibitory control processes 
(the Multi-Source Interference Task) designed to activate the MFC. 
Setting  Healthy control participants and OCD patients recruited from the general community. 
Participants  Nineteen OCD patients (10 males and 9 females) and 19 age-, sex-, education-, and 
intelligence-matched control participants recruited from the general community. 
Main Outcome Measures  Psychometric measures of symptom severity, Multi-Source Interference 
Task behavioral performance, blood oxygen level–dependent activation, and proton magnetic 
resonance spectroscopy brain metabolite concentrations. 
Results  Multi-Source Interference Task behavioral performance did not differ between OCD patients 
and control subjects. Reaction time interference and response errors were correlated with blood 
oxygen level–dependent activation in the dorsal anterior cingulate region in both groups. Compared 
with controls, OCD patients had greater relative activation of the supplementary motor area and 
deactivation of the rostral anterior cingulate during high- vs low-conflict (incongruent > congruent) 
trials. Patients with OCD also showed reduced levels of neuronal N-acetylaspartate in the dorsal 
anterior cingulate region, which was negatively correlated with their blood oxygen level–dependent 
activation of the region. 
Conclusions  Hyperactivation of the MFC during high- vs low-conflict conditions in patients with OCD 
may be a compensatory response to a neuronal abnormality in the region. This relationship may 
partly explain the nature of inhibitory control deficits that are frequently seen in this group and may 
serve as a focus of future treatment studies. 
INTRODUCTION 
Neurobiologic and neuropsychologic models of obsessive-compulsive disorder (OCD) have linked 
obsessive and compulsive symptoms to deficits of response control and inhibition.1-9 Such deficits 
putatively reflect a reduced capacity of patients with OCD to inhibit intrusive or ritualistic cognitions 
and motor response tendencies2 and have been linked to increased volume10 and excessive activity 
of some brain regions, including the medial frontal cortex (MFC), ventral frontal cortex, and basal 
ganglia.2, 11-17 Recent functional magnetic resonance imaging (fMRI) studies of OCD patients have 
associated MFC-related hyperactivations in the dorsal (dAC) and rostral (rAC) anterior cingulate 
regions with specific dimensions of inhibitory control, such as response conflict detection and 
resolution and sensitivity to errors.18-21 
 
Although the neural basis of inhibitory control deficits in OCD remains largely unknown, studies 
using proton magnetic resonance spectroscopy (1H-MRS) have found specific reductions in AC levels 
of N-acetylaspartate (NAA) in medicated22 and drug-naïve OCD patients.23 N-acetylaspartate is a 
metabolite found primarily in neurons, and reduced levels are thought to index neuronal loss, 
dysfunction, or both.24-25 This suggests that hyperactivation of the MFC, which is commonly seen in 
fMRI studies of OCD patients, may reflect a compensatory response to a primary neuronal deficit.11, 
26 However, direct associations between these 2 measures have not previously been demonstrated 
as no study to date, to our knowledge, has acquired both functional and biochemical indices of 
neuronal integrity in the same individual. 
 
In this study, we sought to clarify the nature of MFC hyperactivation in OCD patients using a 
multimodal approach combining fMRI and 1H-MRS. We focused primarily on the superior MFC, 
incorporating the paralimbic component of the dAC, given strong previous evidence for its 
involvement in inhibitory control and dysfunction in OCD.11, 19-20,27-31 We used a functional 
paradigm, the Multi-Source Interference Task (MSIT), that has been shown to robustly activate the 
dAC and the supplementary motor area (SMA), including the pre-SMA, in individual healthy and 
neuropsychiatric individuals32-34 and that incorporates elements of inhibitory control (eg, response 
conflict detection and resolution) that are relevant for understanding the behavioral disturbances 
seen in patients with OCD.19 Concurrently, we acquired volume-localized 1H-MRS measures from 
the medial wall region that we expected would be activated by the functional task. 
 
Based on previous work, we hypothesized that patients would show increased activation of this 
medial wall complex during MSIT performance compared with controls,27, 35-36 that 
concentrations of NAA would be reduced in the patient group,22 and that there would be an inverse 
relationship between concentrations of NAA and dAC activation. Such a relationship would 
constitute preliminary evidence supporting the notion of compensatory MFC hyperactivation driven 
by a neuronal deficit. 
 
 METHODS 
PARTICIPANTS 
 
We recruited 21 patients with OCD from the general community through advertisements in local 
newspapers and community services. All the patients were required to (1) have a current IQ greater 
than 80, (2) be medication free or stable on their medication dose for at least 1 month, and (3) have 
no other current Axis I psychiatric diagnosis. All participants with a history of significant head injury 
(ie, loss of consciousness for >5 minutes, hospitalization requiring a >1-night stay, or significant 
postconcussion syndrome), neurologic disease, electroconvulsive therapy, impaired thyroid function, 
and corticosteroid use were excluded. All the participants gave written informed consent to 
participate in this study, which was approved by the Melbourne Health Research and Ethics 
Committee. 
 
One patient with OCD was excluded because of an incidental MRI finding (an infarct in the superior 
parietal area), and 1 was excluded owing to inability to complete the task (1 arm became numb 
while in the scanner and the patient could not respond properly). The remaining OCD patients were 
case matched based on age, sex, education, and intelligence to a sample of 19 controls selected 
from a larger control sample obtained as a part of an ongoing program of research37 such that there 
were no significant group differences on any of these measures (matching was done before any 
analyses were performed) (Table 1). At the time of scanning, the OCD group reported mild to 
moderate levels of OCD symptoms (as indexed by the Yale-Brown Obsessive-Compulsive Scale), 
characterized predominantly by contamination and checking compulsions (indexed using the Padua 
Inventory), and moderate levels of cognitive and affective symptoms of depression and physiologic 
and psychological symptoms of anxiety (measured using the Beck Depression Inventory and the Beck 
Anxiety Inventory). There were no patients with prominent hoarding symptoms. Eleven patients 
were receiving stable doses of medication at the time of scanning (fluoxetine hydrochloride [n = 4], 
fluvoxamine maleate [n = 1], citalopram hydrobromide [n = 2], venlafaxine hydrochloride [n = 1], and 
clomipramine hydrochloride [n = 3]). 
 
Table 1. Sample Characteristics a 
 
Diagnoses were established using the Structured Clinical Interview for DSM-IV Axis I disorders 
(including impulse spectrum disorders), Patient Edition.38 All the controls also underwent a 
Structured Clinical Interview for DSM-IV Axis I disorders, Nonpatient Edition. No control subject had 
an Axis I or II disorder, and no patient had comorbid Axis I or II disorders. General intelligence (IQ) 
was estimated using the Wechsler Abbreviated Scale of Intelligence.39 
 
FUNCTIONAL TASK 
 
Full details of the MSIT appear elsewhere.32-33 Briefly, the MSIT is a task that encompasses 
inhibitory control processes designed specifically to probe the human MFC, particularly the dAC-SMA 
complex, in fMRI experiments. The MSIT combines sources of interference from a variety of well-
known paradigms (ie, the Stroop, Flanker, and Simon tasks) and generates a state of high response 
conflict by engaging competing response tendencies that code correct and incorrect outcomes. 
During scanning, participants viewed sets of 3 numbers from 0 to 3, presented in strings of 3, with 1 
number always being different from the other 2. Participants were instructed to indicate the identity 
(not the position) of the number that was different by pressing the appropriate button on a 
response box. Responses were made with 1 of 3 fingers: the index finger to indicate 1, the middle 
finger to indicate 2, and the ring (fourth) finger to indicate 3. During congruent (C) task trials, the 
number always matched the position on the response box and was flanked by the number 0. During 
incongruent (I) task trials, the number never matched the response position and was flanked by 
incongruent numbers. Participants were informed that scans would begin and end with fixation for 
60 seconds, between which they would see 8 alternating block pairs of C and I trials (ie, 16 blocks) 
lasting 30 seconds per block (eg, FCICICICIFCICICICIF). Stimulus and interstimulus intervals were 2000 
and 500 milliseconds, respectively. For all the trials, participants were instructed to answer as 
quickly and accurately as possible. During the scanning trials, behavioral reaction times (RTs) and 
percentage error scores were recorded via a notebook computer. Before scanning, all the 
participants completed a practice run of the task consisting of 1 block of 12 C trials and 1 block of 12 
I trials. 
 
IMAGING ACQUISITION AND PREPROCESSING 
 
All individual MRI sequences were acquired in a single scanning session using a 3-T magnetic 
resonance scanner (GE Signa Horizon LX; GE Healthcare, Milwaukee, Wisconsin). Before scanning, 
participants were introduced to a "mock scanner" to familiarize them with the MRI environment (for 
approximately 30 minutes). After the mock session, participants were taken to the actual scanner 
and had their head stabilized using a Velcro strap over the forehead. Scanning sequences consisted 
of a scout localizer, fMRI, T1-weighted anatomical sequence, and 1H-MRS, in that order. Imaging 
data were transferred to a Linux 2.4.27 workstation (Debian Sarge) for image preprocessing and 
analysis. 
 
Functional MRI data were acquired as a series of single-shot gradient-recalled echo-echo planar 
imaging volumes providing T2*-weighted blood oxygen level–dependent (BOLD) contrast. The image 
acquisition parameters for the functional scans were repetition time, 3000 milliseconds; echo time, 
40 milliseconds; flip angle, 60°; field of view, 24 cm; and a 128 x 128 matrix, producing a voxel size of 
1.875 x 1.875 x 4.0 mm and 25 sections for full-brain coverage. The first 4 images in each run were 
automatically discarded to allow the magnetization to reach steady-state equilibrium. For each 30-
second block in the experiment, 10 volumes were acquired, resulting in a total of 80 volumes for the 
C condition and 80 volumes for the I condition. 
 
Volume-localized 1H-MRS findings were recorded using a short-echo point resolved spectroscopy 
sequence (repetition time, 3000 milliseconds; echo time, 30 milliseconds; number of signals 
acquired, 128; and nominal voxel size, approximately 6.5 cm3) from the dAC bilaterally (Figure 1). 
The MRS voxels were placed in each hemisphere, separated by the medial wall boundary of the 
frontal lobes, to encompass the dAC. The posterior boundary of the voxel was approximately 10 mm 
posterior to a vertical line from the anterior commissure orthogonal to the anterior commissure–
posterior commissure line. The inferior border was approximately 5 mm superior to the top edge of 
the corpus callosum, and the medial border was 1 to 2 sections lateral to the parasagittal section on 
the T1 structural image for each hemisphere. For volume-localized spectra, absolute levels of NAA, 
glutamate + glutamine, creatine + phosphocreatine, choline, and myoinositol were measured. 
 
Figure 1. Volume-localized proton magnetic resonance spectroscopy (sagittal and axial orientations) 
shows considerable overlap with the group of activated clusters in the dorsal anterior cingulate region 
(displayed at the commonly reported threshold of z > 3.0) for controls (A) and patients with 
obsessive-compulsive disorder (B). Images are displayed on a canonical structural magnetic resonance 
image (Montreal Neurological Institute, Talairach brain). C, Sample magnetic resonance spectroscopy 
spectrum from the dorsal anterior cingulate region highlighting the 5 main metabolite peaks: N-
acetylaspartate compounds (NAA), creatine + phosphocreatine (Cr), choline compounds (Cho), 
glutamate + glutamine (Glx), and myoinositol (mI). IU indicates arbitrary institutional units. 
 
STATISTICAL ANALYSES 
Individual demographic measures of sex, handedness, age, education, and IQ were compared across 
groups using univariate analyses of variance in SPSS version 11.0 (SPSS Inc, Chicago, Illinois). Analyses 
of behavioral data were conducted using repeated-measures analysis of variance, with task 
condition (C vs I blocks) as the within-subject effect and group (controls vs OCD patients) as the 
between-subject effect. Response errors were calculated by summing all commission (eg, responding 
"1" when the correct answer was "2") and omission errors (missed responses) across the C and I 
trials. The response error variable was log10 transformed
 to ensure normality of distribution.40 
Interference effects were calculated by subtracting the mean RT for the C trials across all blocks from 
the mean RT of the I trials across all blocks.  
Analysis of the fMRI data was performed using FEAT (fMRI Expert Analysis Tool) Version 5.4 (FMRIB 
Software Library, http://www.fmrib.ox.ac.uk/fsl). The following preprocessing was applied before 
statistical analysis: motion correction using MCFLIRT,41 nonbrain removal using the BET (Brain 
Extraction Tool),42 spatial smoothing using a gaussian kernel of full width at half maximum of 5 mm, 
mean-based intensity normalization of all volumes by the same factor, and high-pass temporal 
filtering (gaussian-weighted least squares fit straight line fitting, with sigma = 30.0 seconds). Time 
series statistical analysis was performed using FILM (FMRIB Improved Linear Model) with local 
autocorrelation correction.43 Individual participant z (gaussian-transformed) statistical images were 
thresholded using clusters determined by z > 2.7 and a whole-brain (corrected) cluster significance 
threshold of P < .05.44 For controls, 16 showed activation of the dAC-SMA region at this threshold, 
and 3 controls showed activation at a lowered z score of 2.33 (whole-brain clusterwise corrected). 
For OCD patients, 16 showed activation of the dAC-SMA region at the higher z > 2.7 threshold, 2 
showed activation at the lower level, and 1 showed no activity above either threshold. In addition, 
we extracted a converted percentage signal change value of the BOLD response (I > C) from the dAC 
cluster maximum of each individual using Featquery in FSL. We used the peak voxel for each 
individual in preference to summing activity over a larger area in a standard space (eg, an area 
around the peak voxel or the MRS volume of interest) to minimize averaging over nonsignificant 
voxels. Preliminary analyses indicated that an individually tailored voxel is representative of the 
overall activated cluster and provides a more reliable association with the behavioral indices of the 
MSIT.  
Group-level analysis was performed using FLAME (FMRIB Local Analysis of Mixed Effects).45-46 For 
within-group analyses, z (gaussianized T/F) statistical images were determined using a threshold of 
z > 4.0, P < .05 (whole-brain clusterwise corrected).44 To facilitate comparisons with existing 
literature,18-19 clusters were visually displayed (eg, Figure 2 and Figure 3) at a commonly reported 
threshold of z > 3.0. For between-group comparisons (OCD vs control), z (gaussianized T/F) statistical 
images were determined using a whole-brain (uncorrected) threshold of z > 3.0, P < .0001. 
Registration to standard space images was performed using FLIRT.41, 47 
Figure 2. Areas of brain activation during performance of the Multi-Source Interference Task in 
controls (A) and patients with obsessive-compulsive disorder (OCD) (B). Both groups showed robust 
activation of the medial walls of the frontal lobes and superior parietal regions. In OCD patients areas 
of relative hyperactivation are shown, including the putamen, inferior frontal, and supplementary 
motor area (C), as is apparent hypoactivation in the rostral anterior cingulate (D). Images are 
displayed in radiologic format. Numbers at the top of each row indicate the section number in 
Montreal Neurological Institute space. Color bars indicate the z score ranges. 
Figure 3. Patterns of task-related activation (hot colors) and deactivation (cold colors) during high- vs 
low-conflict trials (incongruent > congruent) in both groups. Patterns are shown for controls (A) and 
patients with obsessive-compulsive disorder (OCD) (B) and for controls (C) and OCD patients (D) with 
the rostral anterior cingulate cluster differentiating the 2 groups superimposed in yellow. It can be 
seen that this rostral anterior cingulate cluster represents a portion of the significant medial frontal 
cortex deactivation in OCD patients. Images are displayed in radiologic format. Color bars indicate the 
z-score ranges (hot colors for activation and cold colors for deactivation). 
 
Metabolite concentrations derived from 1H-MRS were determined for each region of interest 
(corrected for estimated tissue content) using LCModel software.48 This software used a library of 
reference spectra in a basis set recorded specifically for the scanner and calibrated using the tissue 
water signal as an internal standard. The LCModel-fitting algorithm uses the multiple peaks 
contributing to an individual metabolite spectrum to estimate the tissue content of each 
metabolite.48 The residual signal corresponds to, and is fitted by, additional broad peaks representing 
unknown metabolites and other factors, such as macromolecular components with short T1 
relaxation times. In the analyses, the mean of the left and right hemisphere values for each 
metabolite was used because the values were highly correlated (r = 0.45-0.86; P < .05), with no 
significant differences between them. The MRS parameters used for this study provided robust 
signals for the control and OCD groups, with mean ± SD signal-to-noise ratios of 15.94 ± 2.01 and 
16.45 ± 2.86, respectively, and a mean ± SD full width at half maximum of 0.06 ± 0.01 ppm for both 
groups. All the metabolites showed good reliability of fit as judged from the mean Cramer-Rao lower 
bounds. The mean Cramer-Rao lower bounds values (estimates of the SD of the fit) for NAA, 
creatine + phosphocreatine, choline compounds, myoinositol, and glutamate + glutamine were 5.2, 
5.2, 6.0, 8.4, and 10.3, respectively, for controls and 5.0, 4.9, 5.1, 7.2, and 9.1, respectively, for 
patients with OCD.  
Examination of brain behavior–metabolite associations were conducted using Pearson product 
moment correlations between the percentage signal change value of the BOLD response from the 
dAC cluster maxima of each individual, behavioral indices of RT interference and response errors, 
brain metabolites from 1H-MRS, and symptom severity measures from the Yale-Brown Obsessive-
Compulsive Scale.  
 
RESULTS  
BEHAVIORAL 
Both groups had faster mean ± SD RTs to the C trials (controls: 865 ± 134.99 milliseconds; 
OCD patients: 930 ± 110.62 milliseconds) than to I trials (controls: 1203 ± 187.58 
milliseconds; OCD patients: 1287 ± 153.39 milliseconds; main effect of condition: F1,35 = 
514.50; P<.001). Both groups displayed large and comparable mean ± SD RT interference 
effects (controls: 338 ± 85.31 milliseconds; OCD patients: 357 ± 100.57 milliseconds; main 
effect of group: F1,35 = 2.52; P = .12; task by group interaction: F1,35 = 0.39; P = .54). Both 
groups made fewer response errors (mean ± SD) to C trials (controls: 0.47% ± 0.77%; OCD 
patients: 2.0% ± 2.38%) than to I trials (controls: 4.79% ± 5.89%; OCD patients: 7.39% ± 
7.18%; main effect of condition: F1,35 = 20.92; P<.001). There was no difference in response 
accuracy between the 2 groups (main effect of group: F1,35 = 3.13; P = .09; task by group 
interaction: F1,35 = 0.26; P = .62). 
 
FUNCTIONAL 
 
Within Group 
 
Both groups showed the largest task-related activation (I > C) in the MFC region encompassing the 
dAC and the SMA (Table 2 and Figure 2A and B). This medial cluster of activation was primarily in the 
dAC for controls and was larger and extended more posteriorly into the pre-SMA and SMA proper 
for OCD patients. 
Table 2. Medial Frontal Wall Activation and Relative Group Differences During Task Performance in 
Controls and Patients With OCD a 
The MFC activation was part of a larger network of activated regions for controls, including 9 other 
suprathreshold clusters (P < 5.87 x 10–9 to P < 1.0 x 10–3, clusterwise corrected) in the prefrontal, 
superior parietal, fusiform, cerebellar, and caudate/putamen regions. For OCD patients, 10 
suprathreshold clusters were identified (P < 2.04 x 10–14 to P < 1.0 x 10–3) in regions similar to those 
displayed by controls, with additional clusters in the insula and inferior parietal areas (Table 3 and 
Figure 2A and B). 
Table 3. Additional Areas of Brain Activation and Relative Group Differences During Task Performance 
in Patients With OCD and Controls a 
 
Between Group 
The OCD group showed relative hyperactivation (I > C) in a cluster located in the SMA. Patients also 
showed relative hypoactivation in the rAC (Table 2 and Figure 2C and D). This latter finding was 
contrary to expectations and the results of previous studies, which led us to further investigate 
patterns of task-related activation and deactivation in both groups. These patterns are displayed in 
Figure 3 together with the rAC cluster that differentiated the 2 groups. As can be seen, the apparent 
rAC hypoactivation in OCD patients resulted from greater relative deactivation of this region in the 
patient group during the high- vs low-conflict trials (ie, the I > C contrast revealed greater relative rAC 
deactivation in the OCD group).  
The OCD group showed relatively greater activation in 5 other regional clusters (P < 1.0 x 10–3), with 
the largest being in the superior parietal area. Controls showed greater relative activation in 2 other 
regional clusters (P < 1.0 x 10–3), including the inferior frontal cortex and fusiform gyrus (Table 3 and 
Figure 2C and D).  
Metabolites 
Compared with controls, OCD patients showed significant (P = .01) decreases in NAA concentrations 
(a mean reduction of 6.3%) (Table 4). No other group differences were observed for the other 
metabolites.  
Table 4. Absolute Metabolite Concentrations Obtained From the dAC a 
Brain-Behavioral Associations 
There was no group difference in the mean magnitude of dAC BOLD signal change (I > C) for each 
individual participant's maximal cluster of activation (controls: 1.53%; OCD patients: 1.48%; main 
effect of group: F1,46 = 0.06; P = .81).
 For controls, there was a positive correlation between dAC 
BOLD signal change and RT interference and total response errors (r = 0.68, P = .001; r = 0.61, 
P = .005, respectively). Similarly, OCD patients also showed a significant correlation between dAC 
BOLD signal change and RT interference and response errors (r = 0.46, P = .03; r = 0.47, P = .03, 
respectively).  
As predicted, OCD patients showed a negative association between dAC BOLD signal change and 
levels of dAC NAA (r = –0.39; P = .05) (Figure 4). This association was not apparent in the control 
group (r = –0.10; P = .69). A direct between-group comparison of the 2 correlation coefficients was 
not significant (z = –0.88; P = .19) and would require a sample size of 59 to achieve significance at 
P <.05. 
Figure 4. Scatterplot of the relationship between the percentage of blood oxygen level–dependent 
(BOLD) signal change and N-acetylaspartate (NAA) concentrations in the dorsal anterior cingulate of 
patients with obsessive-compulsive disorder. 
Controls showed a trend-level association between behavioral performance and concentrations of 
myoinositol (RT interference: r = 0.36, P = .07; response errors: r = 0.49, P = .02) that was not 
apparent in OCD patients (RT interference: r = 0.20, P = .21; response errors: r = 0.02, P = .50). The 
differences between groups for the 2 correlation coefficients were not significant for the association 
between myoinositol and response errors (z = 1.46; P = .07) or for the association between NAA and 
BOLD signal change (z = –0.09; P = .19). The sample size required to achieve significance at P <.05 
would be 24 for the myoinositol–response errors association and 59 for the NAA–BOLD signal change 
association. No other brain-behavior associations between measures (including symptom severity 
and depressive symptoms) were identified.  
Effects of Psychotropic Treatment 
Eleven OCD patients were receiving psychotropic therapy at the time of testing, which may have 
affected their behavioral performance, brain function, or biochemistry. Reanalysis of the data 
comparing the 11 medicated OCD patients with the 8 unmedicated patients did not reveal any 
differences between these 2 OCD groups on measures of task performance, symptom severity, dAC 
activation, or metabolite concentrations. However, there was a trend for medicated patients to have 
lower glutamate + glutamine concentrations relative to unmedicated patients (mean ± SD, 
9.41 ± 1.17 vs 10.32 ± 0.87 institutional units; F1,13 = 3.48; P = .08).
  
 
COMMENT  
To our knowledge, this is the first study to combine fMRI and 1H-MRS measurements to investigate 
the neural correlates of inhibitory control in OCD patients. We found that during performance of a 
task encompassing inhibitory control processes, OCD patients showed evidence of relative 
hyperactivation of the MFC during high- vs low-conflict conditions. Although the peak group 
difference was in the SMA, inspection of the within-group results suggests that this effect resulted 
from OCD patients activating a more spatially extended dAC/SMA region rather than a focal 
difference in the SMA alone. Consistent with the predictions, OCD patients showed a reduction in 
the concentration of dAC NAA that was inversely correlated with the BOLD signal change in the same 
region. Taken together, these findings provide new evidence for a biochemical basis to the MFC 
hyperactivation seen in OCD and suggest that this excessive activation may reflect a compensatory 
response to underlying neuronal abnormalities. This results in patients recruiting a larger region of 
the MFC (ie, as defined by a greater spatial extent or number of activated voxels) to perform at 
appropriate levels. However, given the modest strength of the association between dAC BOLD signal 
change and dAC levels of NAA, we consider this a novel finding that requires replication. 
 
Similar to other studies33-34 of the MSIT in controls and psychiatric patients, both groups in this 
study showed significant and robust activation of the dAC and the closely connected dorsal 
premotor regions (pre-SMA/SMA). The relative hyperactivation of the MFC in OCD patients was 
consistent with the predictions and previous findings.11, 19-20,31 Overall, the group-level analysis 
showed that the extent of activation (ie, the number of activated voxels) in OCD patients was 
approximately twice that in control subjects (747 vs 357 voxels), with no significant group 
differences in the magnitude of the dAC BOLD response. When taken together with the present 
findings of decreased NAA levels in the dAC of individuals with OCD, 1 possibility is that to achieve 
adequate task performance, the patient group recruited a larger cluster of medial wall regions (ie, 
pre-SMA/SMA) to compensate for biochemical abnormalities in the region. Alternatively, it is 
possible that the heightened activation of dorsal premotor regions in patients has primary, rather 
than compensatory, relevance to the pathogenesis of OCD. This would be consistent with other 
studies of premotor cortex hyperexcitability in OCD patients,49-52 particularly during response-
generation tasks.26 In either case, it is clear that further studies are needed to clarify the specificity 
of functional abnormalities of the MFC in OCD in the context of cognitive and psychomotor 
demands. 
 
The magnitude of this dAC BOLD response was associated with task performance in both groups and 
was unrelated to symptom severity in patients. This latter finding contrasts with recent studies18, 20 
that have reported associations between the magnitude of increased dAC activity and severity of 
illness. The OCD sample was characterized by moderate levels of symptom severity, comparable 
with these studies, suggesting that differences in symptom severity are unlikely to explain the 
discrepancy in findings. The present findings are consistent with those of Maltby et al,19 who 
investigated more severely ill patients using the go/no-go task of inhibitory control. These 
researchers found hyperactivity in the MFC, which was unrelated to symptom severity. Future 
studies using similar tasks in the context of symptom provocation paradigms or different symptom 
profiles may elicit patterns of activation that are more closely related to symptom measures.53-57 In 
addition, studies that focus on specific events (eg, using an event-related fMRI paradigm to model 
brain activity associated specifically with response errors) may have greater sensitivity in extracting 
such relationships.18, 20 
 
The finding of reduced NAA levels is consistent with the 2 previous 1H-MRS studies of the AC in 
OCD.22-23 We extended this work by demonstrating a negative correlation, apparent only in 
patients, between dAC NAA levels and function, as indexed by the BOLD response. N-acetylaspartate 
is a metabolite produced in neuronal mitochondria and is thought to reflect neuronal density and 
functional viability.24, 58 It remains unclear whether reduced levels reflect neuronal loss or a state 
of (potentially reversible) neuronal dysfunction. Whereas Ebert et al22 interpreted their findings of 
reduced NAA levels in OCD patients as evidence of neuronal loss in the AC region, histopathologic 
data on this issue are lacking. More recently, Jang et al23 found that the baseline NAA reductions in 
the dAC of drug-naïve OCD patients could be partly reversed with 12 weeks of citalopram treatment, 
suggesting that the reduced NAA levels in this study may reflect neuronal dysfunction rather than 
loss. More specifically, it has been suggested that NAA concentration reflects mitochondrial 
function.59 After its release from neurons, NAA is taken up and hydrolyzed by oligodendrocytes60-
61 to act as a source of acetyl groups in a variety of metabolic processes, including myelin 
synthesis,62 lipid repair/fatty acid synthesis,63 osmotic regulation,64 and anti-inflammatory 
action.65 Reduced dAC NAA levels may, thus, reflect a variety of underlying metabolic and 
biochemical changes that, when considered in the context of the present findings, suggest that OCD 
patients have fewer healthy neurons in the region, necessitating the recruitment of adjacent and 
other task-related brain regions (eg, the SMA, the lateral premotor, and the superior parietal) to 
perform at levels comparable with controls. This finding is supported by increasing evidence that 
NAA is critical for optimal cognitive functioning (for reviews, see Yeo et al66 and Valenzuela et al67). 
However, the precise nature of the relationships among BOLD signal change, neuronal activity levels, 
and the physiologic role of NAA in neurons has yet to be fully elucidated. Further investigations of 
the exact relationship between BOLD signal change (measured by means of fMRI) and NAA 
concentration (measured by means of 1H-MRS) in controls or patients with focal brain regions is 
warranted before more conclusive statements can be made. 
 
As a secondary finding of this study, the whole-brain comparison of OCD patients and controls also 
showed significantly greater deactivation of the rAC region during the high- vs low-conflict trials. This 
pattern of task-related deactivation of the rAC and adjacent MFC is a typical finding in functional 
neuroimaging experiments and is thought to reflect a shift from greater self-referential, or self-
directed, mental activity (including subjective anxiety)68 to focused attention during task 
performance.69 The increased rAC deactivation seen in OCD patients may reflect abnormally high 
levels of performance anxiety, which may form a part of the primary functional abnormality of the 
disorder. However, whether such activity relates to task anticipation or performance appraisal 
cannot be determined herein. A focus for future studies will be to undertake more detailed 
characterizations of the baseline default state in OCD patients. 
 
One limitation of the present study was the long duration of illness in patients (average illness 
duration of approximately 13 years), which means that the effects of prolonged illness and 
treatment on the findings cannot be excluded. However, note that serotonergic antidepressant 
medication tends to decrease activation in the MFC of OCD patients,70-71 which is, therefore, 
unlikely to account for the finding of hyperactivation of the MFC in patients. A second limitation was 
the focus on the MFC, particularly the dAC, meaning that we did not acquire MRS data from other 
brain regions that are also important in the inhibitory control network implicated in OCD (eg, the 
inferior frontal gyrus).2, 72 Thus, the anatomical specificity of the MRS findings is unclear. Finally, 
some of the analyses (eg, comparison of medicated vs unmedicated patients) may have been 
underpowered and warrant more comprehensive examination. Future studies examining the 
relationship between neuronal and functional markers of AC integrity in OCD, and how these vary as 
a function of symptom profile and treatment history, will represent a useful extension to this study. 
 
Taken together, the behavioral, functional, and biochemical measures of the MFC indicate that OCD 
is associated with increased, presumably compensatory, activation in this region that may be 
underpinned by reduced neuronal integrity and viability. Future studies should consider the effects 
of treatment on brain metabolites and differences in brain activation during baseline or control 
conditions in OCD patients, as these may provide complementary data about the functional 
neuropathologic features of OCD. Future OCD research should also use tasks that encompass other 
and more specific aspects of inhibitory control (eg, the stop-signal paradigm)72 and further evaluate 
the state vs trait nature of dysfunction (eg, by examining unaffected relatives of affected patients). 
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 Figure 2. Areas of brain activation during performance of the Multi-Source Interference Task in controls (A) 
and patients with obsessive-compulsive disorder (OCD) (B). Both groups showed robust activation of the 
medial walls of the frontal lobes and superior parietal regions. In OCD patients areas of relative 
hyperactivation are shown, including the putamen, inferior frontal, and supplementary motor area (C), as is 
apparent hypoactivation in the rostral anterior cingulate (D). Images are displayed in radiologic format. 
Numbers at the top of each row indicate the section number in Montreal Neurological Institute space. Color 
bars indicate the z score ranges. 
 
 
  
 
  
 
